Learn how Talvey plus Tecvayli cut the risk of myeloma progression or death by 89%, how the combination is given and what it may mean for daily life.

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma […]

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

Johnson & Johnson has reported promising results for TECVAYLI® and TALVEY®, demonstrating an 89% reduction in disease progression risk in myeloma patients.

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further...

Johnson & Johnson (NYSE: JNJ) reported positive topline results from the Phase 3 MonumenTAL-6 trial in adults with relapsed or refractory multiple myeloma after 1–4 prior therapies, including an anti-CD38 antibody and lenalidomide. The study compared TECVAYLI + TALVEY (Tec-Tal) and TALVEY + pomalidomide (Tal-P) against investigator’s choice of EPd or PVd standard regimens.According to Johnson & Johnson, Tec-Tal reduced the risk of disease progression or death by 89% (HR 0.11; 95% CI 0.08–0.16; p<0.0001) and the risk of death by 62% (HR 0.38) versus standard of care, with Tal-P reducing progression or death risk by 73% (HR 0.27; 95% CI 0.2–0.35). Both investigational arms met the primary endpoint of progression-free survival, and safety was described as consistent with the known profiles of each monotherapy. An Independent Data Monitoring Committee recommended unblinding at the first interim analysis, and full data will be presented at a future medical meeting and shared with regulators.

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.

'Combinations represent additional options for early-line treatment,' researcher says

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

Johnson & Johnson said TALVEY plus DARZALEX FASPRO combinations improved progression-free survival in the Phase 3 MonumenTAL-3 multiple myeloma study.

New research reveals the effectiveness of the TALVEY® and DARZALEX FASPRO® combo, achieving significant survival rates in multiple myeloma patients. Find out more about this groundbreaking treatment.

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of...

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

Buy Talquetamab (Talvey) injection online in India at a genuine price. Call +91 9967979080 for latest cost, access support & safe delivery.

 Geachte voorzitter, Het kabinet stelt de Kamer hierbij op de hoogte van de prijsonderhandelingen voor de sluisgeneesmiddelen Tecvayli (teclistamab) en Talvey (talquetamab). Deze zogenaamde bispecifieke antilichamen worden gebruikt bij de behandeling van volwassen patiënten met multipel myeloom (de ziekte van Kahler) die al drie eerdere behandelingen gehad hebben en bij wie de ziekte is teruggekomen. Zorginstituut Nederland (hierna: Zorginstituut) heeft eerder geadviseerd om deze geneesmiddelen, na succesvolle prijsonderhandelingen, te vergoeden1,2. Ondanks intensieve pogingen om afspraken t…

TALVEY is an antibody that is used to treat a form of blood cancer called multiple myeloma. It is used to treat adult patients whose cancer came back after, or did not respond to, at least four prior lines of therapy.

With longer trial follow-up, 79% response seen in disease resistant to therapy

YouTube video by Dr. Rob Swanda

Johnson & Johnson announced on June 15 new results from the phase II RedirecTT-1 study evaluating the investigational combination of Talvey (talquetamab-tgvs), the first U.S. FDA-approved GPRC5D-directed bispecific antibody, and Tecvayli (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific antibody. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]

Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and Tecvayli for RRMM.